Lakefront Biotherapeutics (LKFT) Long-Term Deferred Tax (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Long-Term Deferred Tax for 13 consecutive years, with $185486.5 the latest figure, recorded in Q1 2026.

• Quarterly Long-Term Deferred Tax fell 88.93% year-over-year to $185486.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185486.5 (down 88.93% YoY) and the FY2025 annual result came in at $221901.1, down 86.77% from the prior year.
• Long-Term Deferred Tax eased to $185486.5 in Q1 2026 per LKFT's latest filing, from $221901.1 in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for LKFT reached as high as $4.6 million in Q1 2022 and fell as low as $185486.5 in Q1 2026.
• A 5-year average of $1.4 million and a median of $1.3 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax surged 34.0% — and 2026, when it slumped 88.93%.
• Year by year, Long-Term Deferred Tax stood at $1.6 million in 2022, then dropped by 19.3% to $1.3 million in 2023, then soared by 34.0% to $1.7 million in 2024, then sank by 86.77% to $221901.1 in 2025, then fell by 16.41% to $185486.5 in 2026.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $185486.5, $221901.1, and $953605.7 for Q1 2026, Q4 2025, and Q3 2025 respectively.